Corbus Activates $127.5M ATM, Adding Dilution Overhang to Cash-Burning Biotech
CRBP sits 37% above its 52-week low of $7.12.
Summary
Corbus Pharmaceuticals activated a $127.5 million at-the-market equity program, adding significant dilution potential just as the company burns cash ahead of critical clinical milestones.
Key Events · Financing and Capital Events · CRBP
-
$127.5M ATM Program Activated
A prospectus supplement was filed to sell up to $127.5 million in common stock through Jefferies, with a 3% commission, under the existing $300 million shelf registration.
-
Potential 70% Share Count Increase
At the assumed $9.40 offering price, the ATM could add 13.56 million shares, increasing outstanding shares to ~32.97 million — a roughly 70% increase — with immediate dilution of $2.46 per share to new investors.
-
Ongoing ATM Sales Already Underway
Between June 30 and August 6, 2026, the company sold 738,707 shares under the Sale Agreement, raising approximately $6.6 million in proceeds.
-
Cash Runway Reliant on Dilution
The ATM is critical to funding operations, as Corbus reported a wider Q2 loss of $35.0 million and stated its 12-month cash runway depends on continued ATM sales.
Analysis · CRBP · Life Sciences
Just one day after reporting a wider Q2 loss and a cash runway that depends on ongoing dilution, Corbus Pharmaceuticals filed a prospectus supplement to sell up to $127.5 million in common stock through an at-the-market (ATM) program with Jefferies. This move activates the $300 million shelf registration from March 2026 and quantifies the potential dilution: at an assumed price of $9.40, the offering would add 13.56 million shares, swelling the share count by roughly 70% and immediately diluting new investors by $2.46 per share. The company also revealed it had already sold 738,707 shares under this agreement between June 30 and August 6, raising about $6.6 million. For a clinical-stage biotech burning over $30 million per quarter, the ATM provides essential funding but creates a persistent overhang that could cap share price appreciation, especially with key data readouts for CRB-913 in September 2026 and the start of the TEMPO-1 trial on the horizon.
At the time of this filing, CRBP was trading at $9.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188.4M. The 52-week trading range was $7.12 to $20.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.